Jaeb Center for Health Research conducted a randomized controlled trial evaluating the impact of automated insulin delivery ...

For individuals with type 1 diabetes, low-glucose alerts improve the time below range for drivers and reduce the inci ...

The No. 1 reason physicians cite for not prescribing a continuous glucose monitor is its complexity, a roadblock that DME ...

Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient ...

Medtronic (NYSE:MDT) today announced real-world data supporting the use of its smart insulin pen and CGM sensor combination.

Medical device companies presented new data this week at the Advanced Technologies & Treatments for Diabetes conference.

Medtronic reported 4.1% organic revenue growth and 6.2% adjusted EPS growth. See why we upgraded MDT stock to 'Buy' with a ...

Check your alert settings and refer to your device's manual to ensure the alerts are working as expected. Some people who use continuous glucose monitors have reported not receiving or hearing safety ...

Over 13 weeks, adults with type 2 diabetes using an automated insulin delivery (AID) system had a 0.6-percentage point ...

Data from a controlled trial indicates that patients who switched from daily insulin injections to its Omnipod 5 automated ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes | Dexcom ...

Sequel Med Tech has announced that Abbott’s FreeStyle Libre 3 Plus sensor will be the first continuous glucose monitoring device to work with its twiist Automated Insulin Delivery (AID) System powered ...